Cargando…
Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report
RATIONALE: Aggressive variant of splenic marginal zone lymphoma (AV-SMZL) is a very rare disease that is often associated with TP53 mutations and has a poor prognosis. On the other hand, recent advances in genome sequencing techniques enable us to understand the molecular characteristics of rare can...
Autores principales: | Ishiguro, Kazuya, Sasaki, Yasushi, Takagi, Yoshitake, Niinuma, Takeshi, Suzuki, Hiromu, Tokino, Takashi, Hayashi, Toshiaki, Takahashi, Tohru, Igarashi, Tetsuyuki, Matsuno, Yoshihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458248/ https://www.ncbi.nlm.nih.gov/pubmed/32871937 http://dx.doi.org/10.1097/MD.0000000000021938 |
Ejemplares similares
-
Coexistence of nodal marginal zone B-cell lymphoma and multiple myeloma: A case report and literature review
por: Wang, Manzhi, et al.
Publicado: (2022) -
Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia
por: Yao, Mingkang, et al.
Publicado: (2022) -
Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy: A case report
por: Wu, Xueqiong, et al.
Publicado: (2020) -
Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients
por: Hsiao, Liang-Tsai, et al.
Publicado: (2016) -
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)